Product
Recombinant COVID-19 variant vaccine
2 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Single-center, Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Booster Vaccination of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) in Healthy People Aged 18 Years and OlderStatus: Active (not recruiting), Estimated PCD: 2023-07-30
Clinical trial
A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or OlderStatus: Active (not recruiting), Estimated PCD: 2023-07-30